FOLFOX与CF方案新辅助化疗对大肠癌患者免疫功能影响的对比研究

Impact of neoadjuvant chemotherapy with FOLFOX or CF on immune function in patients with colorectal carcinoma

目的探讨FOLFOX方案与CF方案新辅助化疗对大肠癌患者免疫功能的影响。方法入组83例大肠癌患者,其中观察组43例,行FOLFOX新辅助化疗1个周期,对照组40例,行CF方案新辅助化疗1个周期,化疗结束后1周如Karnofsky评分≥80分则行根治性手术。比较2组患者新辅助化疗前及术后第7天、第14天外周血T细胞亚群免疫及血清IgG水平;同时检测50例正常健康人的免疫功能进行对照。结果 3组患者治疗前T细胞亚群及IgG水平均无显著差异;观察组及对照组患者术后第7天外周血T细胞亚群免疫功能及血清IgG水平均下降,术后第14天均有所恢复,但2组间无显著差异。结论经FOLFOX方案与CF方案新辅助化疗对大肠癌患者免疫功能的影响均基本相同,临床上可根据具体情况针对性选用不同方案进行新辅助化疗。

Objective To explore the impact of neoadjuvant chemotherapy with FOLFOX or CF on immune function in patients with colorectal carcinoma.Methods Eighty-three patients with colorectal carcinoma were selected and divided into observation group（n=43） and control group（n=40）.The observation group received neoadjuvant chemotherapy with FOLFOX.The control group received neoadjuvant chemotherapy with CF for one cycle.If Karnofsky score was over 80 in one week after chemotherapy,the control group would receive radical surgery.The levels of peripheral T-lymphocyte subsets and IgG were tested before neoadjuvant chemotherapy 7 and 14 days after operation.The immune function of 50 normal healthy subjects was tested as normal control group.Results The levels of peripheral T-lymphocyte subsets and IgG before neoadjuvant chemotherapy were not significantly different between the study group and the control group.The levels of peripheral T-lymphocyte subsets and IgG 7 and 14 days after surgery decreased in both groups without significant differences.Conclusion The impact of neoadjuvant chemotherapy with FOLFOX or CF on immune function in patients with colorectal carcinoma is basically the same.We can choose either regimen as neoadjuvant chemotherapy.